Cipla is currently trading at Rs. 641.95, up by 7.25 points or 1.14% from its previous closing of Rs. 634.70 on the BSE.
The scrip opened at Rs. 638.40 and has touched a high and low of Rs. 648.00 and Rs. 636.30 respectively. So far 113108 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 696.00 on 22-Jun-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 696.00 and Rs. 628.10 respectively. The current market cap of the company is Rs. 51726.32 crore.
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.
Cipla is going to price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost. The drug will be priced at less than Rs 5,000 per vial for injection 100 mg — amongst the lowest pricing for remdesivir globally.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
